大成生化科技-新(00809)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00809 大成生化科技-新

已收盘 07-30 14:33:47

0.360

-0.010

-2.70%

最高0.365	最低0.340	成交量112.01万
今开0.365	昨收0.370	日振幅6.76%
总市值6.04亿	流通市值6.04亿	总股本16.79亿
成交额39.56万	换手率0.07%	流通股本16.79亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00809","market":"HK","secType":"STK","nameCN":"大成生化科技-新","latestPrice":0.36,"timestamp":1785393227846,"preClose":0.37,"halted":0,"volume":1120085,"delay":0,"changeRate":-0.027027027027027053,"floatShares":1679000000,"shares":1679000000,"eps":0.06,"marketStatus":"已收盘","change":-0.01,"latestTime":"07-30 14:33:47","open":0.365,"high":0.365,"low":0.34,"amount":395577,"amplitude":0.067568,"askPrice":0.385,"askSize":30000,"bidPrice":0.34,"bidSize":40000,"shortable":0,"etf":0,"ttmEps":0.093,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785461400000},"marketStatusCode":5,"adr":0,"listingDate":984672000000,"exchange":"SEHK","adjPreClose":0.37,"openAndCloseTimeList":[[1785375000000,1785384000000],[1785387600000,1785398400000]],"volumeRatio":3.603877,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00809/wiki","defaultTab":"wiki","newsList":[{"id":"1135840697","title":"大成生化科技-新（00809）与农发签订三年期反担保协议 年度服务费上限750万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135840697","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135840697?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:31","pubTimestamp":1785151869,"startTime":"0","endTime":"0","summary":"2026年7月27日，大成生化科技集团有限公司公告称，公司已与吉林省农业发展集团有限公司签订为期三年的《反担保协议》。根据协议，大成生化科技-新将就农发已向金融机构就其附属公司现有及未来银行贷款所提供或将提供的担保，向农发提供反担保，受益人为农发。根据协议，农发所担保的贷款本金总额上限为人民币15亿元。公司预计在截至2029年7月26日止的三个年度内，每年向农发支付的服务费年度上限均为人民币750万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195851745","title":"大成生化科技2026年6月股份变动月报表：生效10合1后股本相应调整","url":"https://stock-news.laohu8.com/highlight/detail?id=1195851745","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195851745?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:59","pubTimestamp":1783069195,"startTime":"0","endTime":"0","summary":"大成生化科技集团有限公司于2026年7月2日披露了截至2026年6月30日止的股份变动月报表。报告期内，公司于2026年6月26日将每10股每股面值0.10港元的普通股及可换股优先股分别合并为1股面值1.00港元，导致注册股本与已发行股本同步调整。截至6月末，公司法定注册股本合计维持在港币6,000,000,000。本次变动主要因股份合并事项生效，报告期内未见新增发行，也无其他购回或注销行动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181382335","title":"大成生化科技：公告已发行股本变动并完成股份合并","url":"https://stock-news.laohu8.com/highlight/detail?id=1181382335","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181382335?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:45","pubTimestamp":1782985559,"startTime":"0","endTime":"0","summary":"大成生化科技于2026年7月2日发布公告，公司已于2026年6月26日实施资本重组，对普通股及可换股优先股进行股份合并。每十股每股面值0.10港元的已发行及未发行股份，合并为每一股面值1.00港元的合并股份。截至2026年5月31日，普通股已发行股份共计16,788,211,527股，库藏股44,560,000股。股份合并后，普通股已发行股份减少15,109,390,375股，占合并前已发行股份总数约90%，调整为1,678,821,152股；库藏股数目相应减少至4,456,000股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"大成生化科技：公告已发行股本变动并完成股份合并","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648505093","title":"大成生化科技(00809)因“10并1”基准进行股份合并而削减151.09亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648505093","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648505093?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:44","pubTimestamp":1782985443,"startTime":"0","endTime":"0","summary":"智通财经APP讯，大成生化科技(00809)发布公告，于2026年6月26日，该公司因“10并1”基准进行股份合并而削减151.09亿股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00809","BK1212","02969","BK1095","BK1160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648068505","title":"大成生化科技(00809.HK)因“10并1”基准进行股份合并而削减151.09亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648068505","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648068505?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:44","pubTimestamp":1782985443,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1095","02969","00809","BK1160","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645816614","title":"大成生化科技(00809)：股份合并将于6月26日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2645816614","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645816614?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:47","pubTimestamp":1782308824,"startTime":"0","endTime":"0","summary":"智通财经APP讯，大成生化科技(00809)发布公告，通函所载股份合并的所有条件均已达成，股份合并将于2026年6月26日生效。合并股份于联交所开始买卖的时间将为2026年6月26日上午九时正。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00809","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183576685","title":"大成生化科技股东周年大会决议全通过 股份合并6月26日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1183576685","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183576685?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:42","pubTimestamp":1782308524,"startTime":"0","endTime":"0","summary":"大成生化科技集团有限公司宣布，于股东周年大会上提呈的所有决议案均以按股数投票方式正式通过。其中多项核心议案获100%赞成票，股份合并计划将于2026年6月26日生效。公告显示，股份合并方案已满足所有生效条件，联交所已批准合并股份上市及买卖。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"大成生化科技股东周年大会决议全通过 股份合并6月26日生效","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146659221","title":"大成生化科技5月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1146659221","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146659221?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:26","pubTimestamp":1780302388,"startTime":"0","endTime":"0","summary":"大成生化科技集团有限公司于2026年6月1日公布，截至2026年5月31日的股份变动月报。公告显示，公司法定股本及已发行股份整体保持稳定，期间未见新增发行、购回或注销活动。公司目前的注册股本累计为港币6,000,000,000，与上月底一致。其中，普通股法定数量为30,000,000,000股，面值港币0.1元；优先股法定数量同为30,000,000,000股，面值港币0.1元。此外，公司已发行的可换股票据本月并未发生增减变动，发行总额为港币1,726,775,056.9，转换价继续维持港币0.1元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633391434","title":"大成生化科技(00809)附属就生产辅酶Q10菌丝体与神舟生物科技订立合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2633391434","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633391434?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:26","pubTimestamp":1778232395,"startTime":"0","endTime":"0","summary":"智通财经APP讯，大成生化科技 发布公告，本公司间接全资附属公司长春大成大合生物技术开发有限公司与神舟生物科技有限责任公司订立合作协议，据此，神舟生物科技同意委聘大成大合生产辅酶Q10菌丝体。双方亦协定，在神舟生物科技对产品检验合格后，神舟生物科技将根据其月度采购计划向大成大合采购辅酶Q10菌丝体，于2027年1月1日至2028年12月31日期间的最低采购量为1270公吨辅酶Q10。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HBImain","159837","BK1212","BK4581","BK4585","BK4588","00809","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160001767","title":"大成生化科技子公司与神州生物科技就辅酶Q10菌丝体达成合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1160001767","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160001767?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:24","pubTimestamp":1778232299,"startTime":"0","endTime":"0","summary":"大成生化科技集团有限公司宣布，其旗下子公司已与神州生物科技正式签署合作协议，双方将围绕辅酶Q10菌丝体的研发与生产展开深度协作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151195325","title":"大成生化科技更新2026年4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1151195325","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151195325?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:32","pubTimestamp":1777887170,"startTime":"0","endTime":"0","summary":"大成生化科技于2026年5月4日发布了截至2026年4月30日的股份变动月报表。根据公告，公司本月股本结构和已发行股份总数均未发生变动。大成生化科技本月普通股法定股本维持30,000,000,000股，面值每股0.1港元，金额合计3,000,000,000港元；可换股优先股法定股本同样保持30,000,000,000股，金额合计3,000,000,000港元，合并后法定股本总额仍为6,000,000,000港元。大成生化科技在公告中确认，所有股份事项均遵守香港联合交易所有限公司《上市规则》及相关法规要求。本次公告由公司秘书陈昇辉签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629643698","title":"大成生化科技：2025年净利润1.56亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629643698","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629643698?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:07","pubTimestamp":1776985620,"startTime":"0","endTime":"0","summary":"南财智讯4月24日电，大成生化科技（00809.HK）公告，截至2025年12月31日止年度，公司年内溢利为1.56亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604243716840534.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243716840534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147931096","title":"大成生化科技授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1147931096","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147931096?lang=zh_cn&edition=full","pubTime":"2026-04-24 06:55","pubTimestamp":1776984948,"startTime":"0","endTime":"0","summary":"大成生化科技公告称，其董事会已获授一般及无条件授权，可在联交所或其他合规市场购回最多相当于公司已发行股本总数10%的股份。截至公告日，公司已发行股份数为16,788,211,527股，如回购上限全部执行，规模最多可达1,678,821,152股。根据公告，董事会表示，公司回购股份所需资金将来自合法财务来源，依据开曼群岛公司法及相关上市规则安排，可使用公司利润或股票溢价账户等渠道进行。过往股价数据显示，大成生化科技近期股价区间约为每股0.06港元至0.122港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大成生化科技授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134725284","title":"大成生化科技2025年度收入攀升与结构优化并行，氨基酸业务承压净利润显著回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1134725284","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134725284?lang=zh_cn&edition=full","pubTime":"2026-04-24 06:53","pubTimestamp":1776984806,"startTime":"0","endTime":"0","summary":"大成生化科技于本报告期实现收入约22.79亿港元，较2024年的20.01亿港元增长13.9%，主要源于玉米浆糖、氨基酸及玉米淀粉深加工等板块的整体扩张。氨基酸及其相关产品仍为集团核心业务，年内录得约19.44亿港元销售收入，受国际需求、原材料成本及渠道布局变化影响，毛利率由2024年的9.5%降至2025年的8.6%。公司未来战略重点仍围绕提升核心氨基酸业务及产能恢复推进，同时兼顾锅炉翻修、超高温蒸煮、生物燃料等在研或在建项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"大成生化科技2025年度收入攀升与结构优化并行，氨基酸业务承压净利润显著回落","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198324002","title":"大成生化科技2026年3月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1198324002","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198324002?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:40","pubTimestamp":1775032813,"startTime":"0","endTime":"0","summary":"大成生化科技集团有限公司于2026年4月1日披露2026年3月股份变动月报表。报告期截至2026年3月31日，公司各类股份数量及注册股本均未发生变化。大成生化科技集团有限公司本月底法定注册股本总额仍为港币6,000,000,000。普通股方面，在2026年3月底公司已发行16,788,211,527股，另有44,560,000股作为库藏股，总计16,832,771,527股；优先股已发行数量维持在17,267,750,569股，报告期内未有新增发行、回购或注销。公告显示，截至本月末，公司股本总数保持不变。公告由公司秘书陈昇辉签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622879189","title":"大成生化科技(00809)发布年度业绩，年度溢利1.56亿港元 同比减少79.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622879189","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622879189?lang=zh_cn&edition=full","pubTime":"2026-03-28 00:33","pubTimestamp":1774629228,"startTime":"0","endTime":"0","summary":"智通财经APP讯，大成生化科技 发布截至2025年12月31日止年度业绩，该集团取得收益22.79亿港元，同比增加13.86%;本年度溢利1.56亿港元，同比减少79.69%;每股基本盈利1.4港仙。因此，本地供应商倾向将氨基酸产品转售至国内市场，而为应对中国氨基酸产品供应过剩，集团已于2025年第四季度调整氨基酸产量，以达致最佳生产开工率。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"大成生化科技(00809)发布年度业绩，年度溢利1.56亿港元 同比减少79.69%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00809","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873109","title":"大成生化科技(00809)拟“10合1”进行股份合并及更改每手买卖单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873109","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622873109?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:00","pubTimestamp":1774623638,"startTime":"0","endTime":"0","summary":"智通财经APP讯，大成生化科技(00809)发布公告，董事会建议实施股份合并，基准为(i)每10股每股面值0.10港元的已发行及未发行现有股份将合并为1股每股面值1.00港元的合并股份;(ii)每10股每股面值0.10港元的已发行及未发行现有可换股优先股将合并为1股每股面值1.00港元的合并可换股优先股。于本公告日期，现有股份以每手买卖单位2000股现有股份在联交所买卖。受限于及待股份合并生效后，建议将在联交所买卖的每手买卖单位由2000股现有股份更改为1万股合并股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00809","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171186152","title":"大成生化科技拟“10合1”股份合并并将每手买卖单位调至1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1171186152","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171186152?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:17","pubTimestamp":1774621046,"startTime":"0","endTime":"0","summary":"大成生化科技3月27日晚间公告，董事会建议实施股份合并及调整每手买卖单位，相关议案将提交拟于2026年6月24日举行的股东周年大会审议。受限于并待股份合并生效，公司拟把港股市场的每手买卖单位由现行2,000股调整为10,000股合并股份。董事会预期，合并及调整每手买卖单位不会对集团财务状况、营运及股东权益造成重大不利影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620790252","title":"大成生化科技(00809)发盈警 预期2025年净收益约1亿港元至3亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620790252","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620790252?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:42","pubTimestamp":1773844936,"startTime":"0","endTime":"0","summary":"然而，本年度毛利率预期与去年同期的9.5%相比，将降至8.6%。本年度毛利率及净收益预期下降主要归因于以下因素：自2025年年中起，国内玉米颗粒价格上涨导致本集团的经营成本增加;及欧洲联盟对中国内地赖氨酸发起反倾销调查引致国内市场赖氨酸产品供过于求，两者均对本集团的毛利率造成不利影响;及在2024年12月30日完成出售本公司八间附属公司后，未确认一次性收益约 19.62亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00809","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129856475","title":"大成生化科技（00809）：预计2025年度净收益同比下降59.8%至86.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129856475","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129856475?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:40","pubTimestamp":1773844845,"startTime":"0","endTime":"0","summary":"大成生化科技3月18日晚间发布盈利警告称，经对截至2025年12月31日止年度未经审核综合管理账目进行初步评估，预计本年度将录得净收益（税前）约1亿至3亿港元，较2024年度的7.456亿港元大幅下滑，降幅约59.8%至86.6%。\\n\\n营收和毛利方面，本年度收入预计约22.785亿港元，同比增长13.9%；毛利约1.964亿港元，同比增长2.8%。受成本端和售价端双重因素影响，毛利率预计由去年同期的9.5%降至8.6%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.globalbiochem.com","stockEarnings":[{"period":"1week","weight":-0.075},{"period":"1month","weight":-0.075},{"period":"3month","weight":-0.3509},{"period":"6month","weight":-0.4478},{"period":"1year","weight":-0.6864},{"period":"ytd","weight":-0.4308}],"compareEarnings":[{"period":"1week","weight":0.0368},{"period":"1month","weight":0.1208},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0577},{"period":"1year","weight":0.0111},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"大成生化科技集团有限公司是一家主要从事赖氨酸及苏氨酸等生化产品制造及销售业务的投资控股公司。该公司通过四大分部运营业务。氨基酸分部从事赖氨酸及苏氨酸等以玉米为原料的氨基酸产品的生产及销售业务。上游产品分部从事玉米淀粉、玉米蛋白粉、玉米油及其他玉米提炼产品的生产及销售业务。玉米甜味剂分部从事葡萄糖浆、麦芽糖浆、高果糖浆、结晶葡萄糖及麦芽糊精等以玉米为原料的甜味剂产品的生产及销售业务。生物化工醇分部从事生物化工醇、溶雪产品、氢气及液氨等以玉米为原料的生化产品的生产及销售业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.48,"avgChangeRate":-0.004647},{"month":2,"riseRate":0.32,"avgChangeRate":0.008945},{"month":3,"riseRate":0.36,"avgChangeRate":-0.017894},{"month":4,"riseRate":0.5,"avgChangeRate":0.085414},{"month":5,"riseRate":0.52,"avgChangeRate":0.058781},{"month":6,"riseRate":0.346154,"avgChangeRate":-0.044356},{"month":7,"riseRate":0.423077,"avgChangeRate":-0.009646},{"month":8,"riseRate":0.24,"avgChangeRate":-0.030986},{"month":9,"riseRate":0.4,"avgChangeRate":-0.003164},{"month":10,"riseRate":0.48,"avgChangeRate":0.001776},{"month":11,"riseRate":0.4,"avgChangeRate":0.046612},{"month":12,"riseRate":0.44,"avgChangeRate":0.023876}],"exchange":"SEHK","name":"大成生化科技-新","nameEN":"GLOBAL BIO-NEW"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"大成生化科技-新(00809)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供大成生化科技-新(00809)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"大成生化科技-新,00809,大成生化科技-新股票,大成生化科技-新股票老虎,大成生化科技-新股票老虎国际,大成生化科技-新行情,大成生化科技-新股票行情,大成生化科技-新股价,大成生化科技-新股市,大成生化科技-新股票价格,大成生化科技-新股票交易,大成生化科技-新股票购买,大成生化科技-新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"大成生化科技-新(00809)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供大成生化科技-新(00809)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}